How much revenue does Cipla make?

Cipla reported 271.45 billion INR in revenue for fiscal year 2025, up 6.7% from 254.47 billion INR in fiscal year 2024. In Q3 2026 revenue was 69.63 billion INR.

What is Cipla's largest business segment?

Pharmaceutical and Related Products, with 264.46 billion INR or 95% of segment revenue in fiscal year 2025. Next: New Ventures (5%).

Where does Cipla make most of its revenue?

India: 42% of revenue by region in fiscal year 2025, followed by United States of America (29%).

What companies are similar to Cipla?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Sun Pharmaceutical Industries Limited (SUNPHARMA.NS), Torrent Pharmaceuticals Limited (TORNTPHARM.NS), Zydus Lifesciences Limited (ZYDUSLIFE.NS), Mankind Pharma Limited (MANKIND.NS).

Cipla Limited (CIPLA.NS) Stock

About Cipla Limited

Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney disorders, alzh...

At a glance

Cipla reported revenue of 271.45 billion INR for fiscal year 2025, up 6.7% from fiscal year 2024, and net income of 52.73 billion INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 69.63 billion INR, about flat from a year before. Its largest business segment, Pharmaceutical and Related Products, brought in 95% of segment revenue in fiscal year 2025; India was the largest region with 42%.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.